Europe Mass Spectrometry & Chromatography in Diagnostics Market Projected to Reach USD 0.38 Billion Mark by 2030

• Overview
• Table of Content
• Research Methodology
• Download Free Sample

The Europe Mass Spectrometry & Chromatography in Diagnostics Market size was valued at around USD0.22 billion in 2024 and is projected to reach USD0.38 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 9.44% during the forecast period, i.e., 2025-30, cites MarkNtel Advisors in the recent research report. The factors driving the market growth are the rising chronic disease prevalence and the requirement for automation in the diagnosis techniques, increased investments and funds through governments of countries like France, Germany, United Kingdom, Italy, etc., the robust adoption of Artificial Intelligence in the medical devices for diagnostics and the integration of Information Technology.

Various opportunities related to the mass spectrometry and chromatography industry are shaping the potential market growth, including the rising research and development, along with governmental funding in the healthcare sector. For instance, as per Boston Scientific Corporation (2025), the UK National Health Service spends about USD11 billion annually on improving the nation’s medical technology, serving as a potential opportunity for this market. Also, several authorities and companies are providing strict training to individuals to increase the number of trained professionals for operating medical devices, including diagnostic tools that use analytical techniques such as Mass spectrometry and chromatography. In 2025, Boston Scientific Corporation opened a new training center in the United Kingdom called the Institute for Advancing Science (IAS) with an investment of about USD1.1 million to train individuals to use their medical equipment.

Additionally, the manufacturing of hybrid systems including chromatography with mass spectrometry Liquid Chromatography-Mass Spectrometry (LC-MS), and Gas Chromatography-Mass Spectrometry (GC-MS) is transforming the market, leading to the enhanced diagnosis and early detection of chronic diseases including Chronic Kidney Disorders, Cancer, Diabetes, Cardiovascular Diseases, etc. in the European region. Companies like Recipe Chemicals + Instruments GmbH are expanding the hybrid manufacturing of such devices to enhance the early detection and precision of diseases. For instance, the launch of complete kits for LC-MS called ClinSpot that are designed for the detection of analytes present in the blood of newborns can even use dried blood samples.

Moreover, the combination of AI with spectrometry techniques enhances the diagnosis results, contributing to faster patient output with more accuracy and high-throughput data. It leads to reduced operational costs because it requires less manpower, and a large volume of samples can be diagnosed in a shorter duration due to being highly sensitive and automated. Thus increasing the market demand, further states the research report, “Europe Mass Spectrometry & Chromatography in Diagnostics Market Analysis, 2025.”

Europe Mass Spectrometry & Chromatography in Diagnostics Market Segmentation Analysis

Integrated Systems Hold the Largest Market Share

Based on the device type, the market is further bifurcated into Mass Spectrometers, Chromatography Instruments, and Integrated Systems. The Integrated Systems is the leading segment, holding the largest market share of more than 45%. The growth is driven by the high precision and throughput of these systems. Such systems are cost-effective due to the processing of large volumes of samples simultaneously with a smaller workforce.  

Several companies like Bruker’s Corporation, Thermo Fisher, Waters Corporation, Shimadzu, Agilent Technologies, etc., in Europe have actively started manufacturing hybrid systems using mass spectrometry with chromatography, such as Liquid Chromatography-Mass Spectrometry, Gas Chromatography-Mass Spectrometry, etc. This has increased the manufacturing of integrated systems in diagnostics in Europe.  

Germany is the Epicenter of the Regional Market

Germany's dominance in the regional Mass Spectrometry & Chromatography in Diagnostics Industry is due to the robust healthcare sector in Germany, which has a larger number of hospitals, trained professionals, research institutes, etc. Additionally, the Federal Ministry of Education & Research is funding over USD3.7 billion for several research regulations such as Mass Spectrometry for Systems Medicine (MSCoreSys) & Heart Failure Diagnostics with Advanced Mass Spectrometry (DIASyM) to improve the healthcare facilities in the country by identifying chronic disease more precisely and accurately, thus increasing the potential market growth.

Also, Germany is leading in the medical devices market with more than 25% of the total European Market value due to robust research and manufacturing in the medical field within the European region, thus dominating this regional industry.

Competitive Landscape

With strategic initiatives, such as mergers, collaborations, and acquisitions, the leading market companies, including Thermo Fischer Scientific Inc., Tecan Trading AG, Agilent Technologies Inc., Waters Corporation, PerkinElmer Inc., Shimadzu Europe GmbH, Jasco Europe S.R.L., Chromosystems Instruments & Chemicals GmbH, Sentinel Ch. S.p.A., Gerstel GmbH & Co. KG, Recipe Chemicals + Instruments GmbH, and Others are looking forward to strengthening their market positions.

Key Questions Answered in the Research Report

1. What are the industry’s overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares)?
2. What are the trends influencing the current scenario of the market?
3. What key factors would propel and impede the industry across the region?
4. How has the industry been evolving in terms of geography & product adoption?
5. How has the competition been shaping up across various countries?
6. How has the buying behavior, customer inclination, and expectations from product manufacturers been evolving during 2020-30?
7. Who are the key competitors, and what strategic partnerships or ventures are they coming up with to stay afloat during the projected time frame?